{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T20:32:12Z","timestamp":1779136332944,"version":"3.51.4"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100009553","name":"Agentura Pro Zdravotnick\u00fd V\u00fdzkum \u010cesk\u00e9 Republiky","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009553","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003243","name":"Ministry of Health of the Czech Republic","doi-asserted-by":"publisher","award":["NU22-05\u201300402"],"award-info":[{"award-number":["NU22-05\u201300402"]}],"id":[{"id":"10.13039\/501100003243","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.intimp.2023.111159","type":"journal-article","created":{"date-parts":[[2023,11,11]],"date-time":"2023-11-11T04:53:54Z","timestamp":1699678434000},"page":"111159","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"PB","title":["Content and specificity of the Anti-SARS-CoV-2 antibodies in solutions for immunoglobulin replacement therapy"],"prefix":"10.1016","volume":"125","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2105-3462","authenticated-orcid":false,"given":"Tomas","family":"Milota","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jitka","family":"Smetanova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hana","family":"Zelena","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michal","family":"Rataj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Lastovicka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jirina","family":"Bartunkova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2023.111159_b0005","first-page":"13","article-title":"A meta-analysis on the safety and immunogenicity of COVID-19 vaccines","author":"Ashmawy","year":"2022","journal-title":"J Prim Care Community Health"},{"key":"10.1016\/j.intimp.2023.111159_b0010","first-page":"149","article-title":"Immunogenicity of the mRNA-1273 COVID-19 vaccine in adult patients with inborn errors of immunity","author":"van Leeuwen","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.intimp.2023.111159_b0015","first-page":"11","article-title":"Clinical outcomes, immunogenicity, and safety of BNT162b2 vaccine in primary antibody deficiency","author":"Milota","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.intimp.2023.111159_b0020","first-page":"376","article-title":"Efficacy of covid-19 vaccines in immunocompromised patients: systematic review and meta-analysis","author":"Bin","year":"2022","journal-title":"BMJ"},{"key":"10.1016\/j.intimp.2023.111159_b0025","first-page":"59","article-title":"Vaccines and therapeutics for immunocompromised patients with COVID-19","author":"Shoham","year":"2023","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.intimp.2023.111159_b0030","first-page":"22","article-title":"Monoclonal antibody therapies against SARS-CoV-2","author":"Focosi","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.intimp.2023.111159_b0035","first-page":"11","article-title":"Five commercial immunoassays for SARS-CoV-2 antibody determination and their comparison and correlation with the virus neutralization test","author":"\u0160im\u00e1nek","year":"2021","journal-title":"Diagnostics"},{"key":"10.1016\/j.intimp.2023.111159_b0040","first-page":"23","article-title":"The humoral response and antibodies against SARS-CoV-2 infection","author":"Qi","year":"2022","journal-title":"Nat Immunol"},{"key":"10.1016\/j.intimp.2023.111159_b0045","first-page":"50","article-title":"Treatment and management of primary antibody deficiency: German interdisciplinary evidence-based consensus guideline","author":"Hanitsch","year":"2020","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.intimp.2023.111159_b0050","doi-asserted-by":"crossref","DOI":"10.1111\/ejh.13580","article-title":"Treating secondary antibody deficiency in patients with haematological malignancy: European expert consensus","volume":"106","author":"Jolles","year":"2021","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.intimp.2023.111159_b0055","first-page":"149","article-title":"SARS-CoV-2 antibody profile of immune globulin preparations","author":"Park","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.intimp.2023.111159_b0060","first-page":"12","article-title":"Cross-neutralization activity against SARS-CoV-2 is present in currently available intravenous immunoglobulins","author":"D\u00edez","year":"2020","journal-title":"Immunotherapy"},{"key":"10.1016\/j.intimp.2023.111159_b0065","first-page":"22","article-title":"Anti-SARS-CoV-2 antibodies in healthy donor plasma pools and IVIG products\u2014An update","author":"Romero","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.intimp.2023.111159_b0070","first-page":"176","article-title":"Evolving real-world effectiveness of monoclonal antibodies for treatment of COVID-19","author":"Kip","year":"2023","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.intimp.2023.111159_b0075","first-page":"21","article-title":"SARS-CoV-2 variant evasion of monoclonal antibodies based on in vitro studies","author":"Cox","year":"2023","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.intimp.2023.111159_b0080","first-page":"96","article-title":"Efficacy of IVIG (intravenous immunoglobulin) for corona virus disease (COVID-19): A meta-analysis","volume":"2021","author":"Xiang","year":"2019","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.intimp.2023.111159_b0085","first-page":"163","article-title":"Intravenous immunoglobulins (IVIG) in severe\/critical COVID-19 adult patients","author":"Kwapisz","year":"2023","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.intimp.2023.111159_b0090","first-page":"42","article-title":"Neutralizing SARS-CoV-2 antibodies in commercial immunoglobulin products give patients with X-linked agammaglobulinemia limited passive immunity to the Omicron variant","author":"Lindahl","year":"2022","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.intimp.2023.111159_b0095","first-page":"7","article-title":"Anti-influenza immune plasma for the treatment of patients with severe influenza A: A randomised, double-blind, phase 3 trial","author":"Beigel","year":"2019","journal-title":"LancetRespir Med"},{"key":"10.1016\/j.intimp.2023.111159_b0100","first-page":"7","article-title":"Anti-influenza hyperimmune intravenous immunoglobulin for adults with influenza A or B infection (FLU-IVIG): A double-blind, randomised, placebo-controlled trial. Lancet","author":"Davey","year":"2019","journal-title":"Respir Med"},{"key":"10.1016\/j.intimp.2023.111159_b0105","first-page":"7","article-title":"Understanding T cell responses to COVID-19 is essential for informing public health strategies","author":"Vardhana","year":"2022","journal-title":"Sci Immunol"},{"key":"10.1016\/j.intimp.2023.111159_b0110","first-page":"141","article-title":"Update: Vaccines in primary immunodeficiency","author":"Bonilla","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.intimp.2023.111159_b0115","first-page":"42","article-title":"High prevalence of likely passively acquired anti-TPO and anti-GAD autoantibodies in common variable immunodeficiency","author":"Milota","year":"2022","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.intimp.2023.111159_b0120","first-page":"104","article-title":"Characterization of antibodies in human immunoglobulin products from different regions worldwide","author":"Serra","year":"2021","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.intimp.2023.111159_b0125","first-page":"42","article-title":"Immunogenicity of anti-SARS-CoV-2 vaccines in common variable immunodeficiency","author":"Arroyo-S\u00e1nchez","year":"2022","journal-title":"J Clin Immunol"}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576923014856?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576923014856?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T18:04:27Z","timestamp":1761588267000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576923014856"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":25,"alternative-id":["S1567576923014856"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2023.111159","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Content and specificity of the Anti-SARS-CoV-2 antibodies in solutions for immunoglobulin replacement therapy","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2023.111159","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"111159"}}